Cellectar Biosciences Shares Higher

Cellectar Biosciences gained 7% in morning trade Tuesday after its phospholipid drug conjugate research program generated numerous PDC molecules that show significant improved pharmacologic activity versus the payload molecule alone in tumor treatment.

Utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the company’s PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells. “The rapid advancement and positive data from these research programs, coupled with our ongoing collaborations, further validate the unique capabilities and broad utility of our PDC platform,” said CEO Jim Caruso.

Leave a Comment